MedWatch

Questions about Demant's future remain as 2022 nears

Market shares have been won, and the company is ending 2021 with a bigger foothold and a better bottom line than when the year began. While the smoke of the corona crisis dissipates, uncertainty remains for 2022 forecasts, and the future at large.

Photo: Demant / PR

One could be forgiven for thinking that Demant is a stable and perhaps even slightly boring company in which to invest.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs